Gastroenterology Today Autumn 2020

More documents

Recommendations

Info

NEWS Simpler diagnostic process for adults with suspected coeliac disease could reduce NHS waiting lists and improve patient health faster The British Society of Gastroenterology (BSG) has issued interim guidance, pending the publication of its new Coeliac Guidelines in 2021, so that some adults with suspected coeliac disease can now be diagnosed based on blood test results alone, cutting out the long wait for an endoscopy with biopsy. Diagnosis of coeliac disease in adults is usually a two-step process, a blood test to look for antibodies followed by an endoscopy with biopsy to look for damage to the intestine. Early in the coronavirus pandemic, the BSG recommended that non-emergency endoscopies should be paused to protect NHS staff and patients from coronavirus transmission. This meant that many people with suspected coeliac disease have been unable to have an endoscopy as part of their diagnosis. Hilary Croft, Chief Executive of Coeliac UK said: “Coeliac UK has previously called for the national guidelines to review the evidence for adult no-biopsy diagnosis and so fully supports the BSG’s new position. This will enable a greater number of people to gain a faster diagnosis, without the need to wait for an endoscopy at the hospital. Getting an accurate diagnosis of coeliac disease means keeping gluten in the diet throughout the testing process - a difficult feat when waiting lists are long and people feel unwell.” The interim guidance published due to the impact of Covid-19 on endoscopy waiting lists, suggests that a no-biopsy diagnosis can be used for adults under 55 years of age with symptoms of coeliac disease who: • Don’t need an endoscopy to rule out other conditions • Have antibody levels (IgA tissue transglutaminase) at least 10 times the upper limit of normal • Have a second positive antibody blood test (endomysial antibodies (EMA) or tissue transglutaminase if EMA isn’t available) A GP can request the initial antibody blood test but the decision about whether an endoscopy and biopsy is needed, and the final diagnosis of coeliac disease, should be made by a gastroenterologist. The impact of this new diagnosis pathway will be closely monitored, and data is being collected to assess the impact of this new approach for adults. For children, since 2013, guidelines have recommend a no-biopsy diagnosis for some children. “These guidelines are good news for those who meet the criteria for a no-biopsy diagnosis who will be able to start to feel better sooner on a gluten free diet, the only treatment for coeliac disease. However, those that do not meet the criteria for no-biopsy diagnosis are likely to face long waiting times as endoscopy services begin a phased return. Access to blood tests may still be limited at the moment, so we encourage people to speak with their GP for more information about diagnosis of coeliac disease if they are experiencing symptoms,” continued Ms Croft. Coeliac disease is not an allergy or an intolerance but an autoimmune disease where the body’s immune system damages the lining of the small bowel when gluten, a protein (found in wheat, barley and rye) is eaten. There is no cure and no medication; the only treatment is a strict gluten free diet for life. 1 in 100 people in the UK has coeliac disease but only 30% of those with the condition have been diagnosed. There are an estimated half a million people in the UK who have the condition yet don’t know it. There is a wide range of symptoms associated with coeliac disease. Some symptoms may be confused with irritable bowel syndrome (IBS) or wheat intolerance, while others may be put down to stress or getting older. To make it easier to understand if symptoms are possibly due to coeliac disease and discuss further testing with your GP, Coeliac UK has developed a self assessment test to make it easier to take that first step to diagnosis. Go to www.isitcoeliacdisease.org.uk to take the online assessment. WHY NOT WRITE FOR US? GASTROENTEROLOGY TODAY - AUTUMN 2020 Gastroenterology Today welcomes the submission of clinical papers and case reports or news that you feel will be of interest to your colleagues. Material submitted will be seen by those working within all UK gastroenterology departments and endoscopy units. All submissions should be forwarded to info@mediapublishingcompany.com 16 If you have any queries please contact the publisher Terry Gardner via: info@mediapublishingcompany.com
BIOHIT ULTRA-FAST UFT300 HELICOBACTER PYLORI QUICK TEST NEWS A five-minute urease test for gastric biopsies As lockdown begins to ease and your endoscopy services restart, our UFT300 Helicobacter pylori Quick Test and supporting online training module are more important than ever. BIOHIT HealthCare’s quick and simple to use ultra-fast UFT300 Helicobacter pylori Quick Test is the market-leading kit for the diagnosis of H. pylori infection in both NHS and private endoscopy departments. It offers accuracy and a clinical performance comparable to gold standard methods, 1 Key advantages of the UFT300 Helicobacter pylori Quick Test: allowing a reliable diagnosis to be made in just five minutes. This rapid kit provides the opportunity to test, report and • Results in five minutes treat the patient in a single appointment at the point of • Ready to use care – avoiding unnecessary admin and report editing – and • Easy to use enhances the quality of service. • High accuracy minimises false positives and negatives • Direct results during the endoscopy procedure H. pylori infection is a significant and independent risk factor • Sensitivity 94.3 %, specificity 100 % (compared to histology for gastric cancer and peptic ulcer disease. It is a primary and C 13 urea breath test (C 13 UBT n=1000) cause of chronic gastritis, and leads to atrophy of the gastric • Accuracy 97.5 % compared to histology and C 13 UBT mucosa if left untreated. The innovative BIOHIT UFT300 • Room temperature storage Helicobacter pylori Quick Test is a rapid urease test that has revolutionised the way H. pylori infection is diagnosed and To help users get the most out of the test, BIOHIT offers the reported in endoscopy. Biopsy specimens from the gastric UFT300 Helicobacter pylori Quick Test online training module. mucosa can be tested immediately, and a simple colour This fully interactive training experience is designed for all change determines the presence of urease – produced by H. endoscopy staff and covers a range of topics, including H. pylori – within the sample. With extremely high accuracy and pylori infection, urease tests, and the use and interpretation every result available within five minutes, this ready-to-use of the UFT300 Helicobacter pylori Quick Test. A certificate is test is the preferred choice for endoscopists. awarded on completion of the course. Get in touch with a local representative by contacting: info@biohithealthcare.co.uk 1 Vaira D et al. Accuracy of a new ultrafast rapid urease test to diagnose Helicobacter pylori infection in 1,000 consecutive dyspeptic patients. Aliment Pharmacol Ther 2010; 31, 331-338. GASTROENTEROLOGY TODAY - AUTUMN 2020 BIOHIT HealthCare Ltd Pioneer House, Pioneer Business Park, North Road, Ellesmere Port, CHESHIRE, United Kingdom CH65 1AD Tel. +44 151 550 4 550 info@biohithealthcare.co.uk www.biohithealthcare.co.uk/endoscopy 17
Page 1 and 2: Volume 30 No. 3 Autumn 2020 Gastroe
Page 3: CONTENTS CONTENTS 5 EDITORS COMMENT
Page 6 and 7: FEATURE TRANSPLANTATION DURING THE
Page 8 and 9: FEATURE Table 2 Diagnostic tests av
Page 10 and 11: FEATURE GASTROENTEROLOGY TODAY - AU
Page 12 and 13: FEATURE RETHINKING HOW WE TREAT CON
Page 14 and 15: GASTROENTEROLOGY TODAY - AUTUMN 202
Page 18 and 19: NEWS Cost of constipation still ris
Page 20 and 21: NEWS UEG Week Goes Virtual! UEG Wee
Page 22 and 23: COMPANY NEWS BIOHIT SUPPLIES COVID-
Page 24: Helicobacter Test INFAI ® The most

Gastroenterology Today Autumn 2020

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?